CGT 2
Alternative Names: CGT2Latest Information Update: 28 Jan 2025
At a glance
- Originator Lipigon Pharmaceuticals
- Developer CombiGene
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Lipodystrophy
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for preclinical development in Lipodystrophy in Sweden (Parenteral)
- 31 Dec 2020 Preclinical trials in Lipodystrophy in Sweden (Parenteral), prior to December 2020 (CombiGene pipeline, March 2021)